Regnery, Sebastian
Leiner, Lukas
Buchele, Carolin
Hoegen, Philipp
Sandrini, Elisabetta
Held, Thomas
Deng, Maximilian
Eichkorn, Tanja
Rippke, Carolin
Renkamp, C. Katharina
König, Laila
Lang, Kristin
Adeberg, Sebastian
Debus, Jürgen
Klüter, Sebastian
Hörner-Rieber, Juliane
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 23 January 2023
Accepted: 17 May 2023
First Online: 29 May 2023
Declarations
:
: Patients were treated inside two consecutive prospective registry trials that received local ethics board approval and were conducted according to the declaration of Helsinki. Written informed consent was obtained from all patients before trial inclusion.
: Not applicable.
: J. H.-R. and S. K. received speaker fees from ViewRay Inc. J. H.-R. received speaker fees from Pfizer Inc., travel reimbursement from ViewRay Inc., IntraOP Medical and Elekta Instrument AB as well as grants from IntraOP Medical and Varian Medical Systems outside the submitted work. S.A. and J.D. received grants from Accuray International Sàrl and Merck Serono GmbH outside the submitted work. J.D. received grants from CRI – The Clinical Research Institute GmbH, View Ray Inc., Accuray Incorporated, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A.A. and IntraOP Medical outside the submitted work. T.E. received grants from Ruprecht-Karls Universität Heidelberg, Herbert Kienzle Foundation and Else Kröner-Fresenius Foundation and received travel reimbursement from Bristol-Myers Squibb outside the submitted work.